LICENSE AGREEMENT between TITAN PHARMACEUTICALS, INC. and OCULAR THERAPEUTIX, INC. Dated as of December 6, 2022License Agreement • December 12th, 2022 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
This License Agreement (the “Agreement”) is made and entered into, effective as of December 6, 2022 (the “Effective Date”), by and between Titan Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 400 Oyster Point Blvd., Suite 500, South San Francisco, CA 94080 (“Titan”) and Ocular Therapeutix, Inc., a Delaware corporation, having its principal place of business at 24 Crosby Drive, Bedford, MA 01730 (“Ocular”). Titan and Ocular are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
